<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588653</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03</org_study_id>
    <nct_id>NCT00588653</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease</brief_title>
  <official_title>Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to compare in a blinded fashion four different diagnostic modalities to&#xD;
      detect active small bowel Crohn's disease: a) colonoscopy with ileoscopy; b) small bowel&#xD;
      follow through; c) capsule endoscopy; and d) computed tomography enterography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims:&#xD;
&#xD;
      The aims of this study are as follows: 1) to describe the spectrum of small intestinal&#xD;
      lesions demonstrated by capsule endoscopy (CE) in patients with Crohn's disease; 2) to&#xD;
      determine the inter-observer agreement for recognizing these small intestinal lesions; 3) to&#xD;
      determine the sensitivity, positive predictive value, and accuracy of CE, CT enterography,&#xD;
      small bowel follow-through, colonoscopy with ileoscopy, and all pairwise combinations of&#xD;
      these examinations with a consensus clinical diagnosis for the diagnosis and evaluation of&#xD;
      the extent and severity of small intestinal Crohn's disease; 4) to establish a Crohn's&#xD;
      Disease Capsule Endoscopy Index of Severity (CDCEIS); 5) to describe the spectrum of right&#xD;
      colon lesions demonstrated by CE in patients with Crohn's disease.&#xD;
&#xD;
      Study Design and Methods:&#xD;
&#xD;
      Consecutive adult patients with suspected or definite Crohn's disease seen in the&#xD;
      Inflammatory Bowel Disease Clinic at Mayo Clinic Rochester will be offered enrollment in a&#xD;
      prospective observational trial comparing CE with CT enterography, small bowel&#xD;
      follow-through, colonoscopy, and a consensus clinical diagnosis of Crohn's disease. Seventy&#xD;
      patients will be enrolled, according to the inclusion and exclusion criteria, and written&#xD;
      informed consent will be obtained. Co-investigators in the Inflammatory Bowel Disease (IBD)&#xD;
      Clinic will clinically evaluate all patients, including a history and limited physical&#xD;
      examination. Patients will undergo clinically indicated laboratory tests. Serum will be&#xD;
      stored on all patients for other potential laboratory studies. Patients will complete a&#xD;
      retrospective symptom diary for the week prior to their evaluation at Mayo, and a Crohn's&#xD;
      Disease Activity Index (CDAI) will be calculated.&#xD;
&#xD;
      All patients will have a CT enterography with peroral contrast interpreted by a&#xD;
      co-investigator radiologist. All patients will undergo a clinically indicated colonoscopy&#xD;
      with ileoscopy by a staff co-investigator (not by C.A.S. or the staff co-investigator&#xD;
      interpreting the CE), and a Crohn's Disease Endoscopic Index of Severity (CDEIS) will be&#xD;
      calculated. If no significant small bowel strictures are identified by CT enterography or&#xD;
      colonoscopy with ileoscopy, then patients will subsequently undergo CE. All CE studies will&#xD;
      be read separately by C.A.S. (gastroenterology fellow) and a supervising staff&#xD;
      gastroenterologist co-investigator, each blinded to the other's interpretation. The&#xD;
      interobserver agreement between C.A.S. and the co-investigator staff will be determined.&#xD;
      Patients will lastly have a clinically indicated small bowel follow-through interpreted by a&#xD;
      co-investigator radiologist. All co-investigators will be blinded to the results of the other&#xD;
      imaging modalities until after interpreting their respective studies.&#xD;
&#xD;
      Following each imaging procedure, the interpreting physician will complete both small&#xD;
      intestine and colon anatomy forms. The physician will identify all types of lesions present&#xD;
      and also give both a global evaluation of the severity of lesions found and a global Crohn's&#xD;
      disease activity score indicating one of the following: active Crohn's disease, suspicious&#xD;
      for Crohn's disease, inactive Crohn's disease, or no evidence of Crohn's disease.&#xD;
      Co-investigators representing each of the diagnostic modalities will meet periodically to&#xD;
      review those cases where there is disagreement among the imaging procedures with respect to&#xD;
      the extent and severity of small intestinal Crohn's disease in order to reach a consensus&#xD;
      clinical diagnosis. This consensus clinical diagnosis will serve as the gold standard against&#xD;
      which each of the individual imaging modalities is evaluated. Sensitivity, positive&#xD;
      predictive value, and accuracy of all diagnostic modalities compared to the consensus&#xD;
      clinical diagnosis will be determined. A Crohn's disease capsule endoscopy index of severity&#xD;
      (CDCEIS) will be created after the CE studies have been reviewed by investigators from other&#xD;
      referral centers both inside and outside the United States to determine the inter-observer&#xD;
      agreement (reproducibility) for each type of small bowel lesion identified by CE. Logistic&#xD;
      regression analysis with step-wise deletion will then be utilized to create the CDCEIS using&#xD;
      only those lesions that are reproducible, with the global Crohn's disease endoscopic activity&#xD;
      score from the CE as the dependent variable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, positive predictive value, and accuracy of capsule endoscopy, CT enterography, colonoscopy with ileoscopy, and small bowel follow through using a consensus clinical diagnosis of small bowel Crohn's disease as the reference standard.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe spectrum of right colon lesions visualized by capsule endoscopy in patients with Crohn's disease.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through</intervention_name>
    <description>Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatient of either sex aged 18 to 70 years&#xD;
&#xD;
          -  Patient has suspected or definite Crohn's disease&#xD;
&#xD;
          -  Patient has read, understood, and signed a written informed consent form at visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients who are prisoners, institutionalized individuals, or vulnerable adults&#xD;
&#xD;
          -  Patients immediately in need of abdominal surgery for active gastrointestinal&#xD;
             bleeding, peritonitis, intestinal obstruction, perforation, or intra-abdominal abscess&#xD;
&#xD;
          -  Patients with known or suspected gastrointestinal obstruction due to significant&#xD;
             stricture based upon the clinical symptoms (nausea, vomiting, abdominal distention, or&#xD;
             abdominal pain) confirmed by pre-procedure evaluation. Pre-procedure evaluation&#xD;
             includes CT enterography or small bowel follow through performed at Mayo or previously&#xD;
             at an outside institution which demonstrates mechanical obstruction (mechanical&#xD;
             obstruction defined as small bowel narrowing with pre-stenotic dilatation);&#xD;
             additionally, a high-grade stenotic ileocecal valve or ileocolonic anastomosis found&#xD;
             by colonoscopy.&#xD;
&#xD;
          -  Patients with history of abdominal radiation&#xD;
&#xD;
          -  Patients with known or suspected oropharyngeal or esophageal dysphagia (unless recent&#xD;
             EGD shows no evidence of mechanical obstruction of the esophagus, in cases of&#xD;
             esophageal dysphagia)&#xD;
&#xD;
          -  Patients with pacemakers or other implantable electromedical devices&#xD;
&#xD;
          -  Patients with highly suspected or documented gastroparesis&#xD;
&#xD;
          -  Patients who have used NSAIDs within the previous 2 weeks&#xD;
&#xD;
          -  Patients with an anticipated need for an MRI scan within two weeks after M2A capsule&#xD;
             ingestion (for patients who require a clinically indicated MRI, the MRI should be&#xD;
             performed prior to administration of the M2A capsule)&#xD;
&#xD;
          -  Patients with a creatinine â‰¥ 2.0.&#xD;
&#xD;
          -  Patients with documented reaction to iodinated contrast material.&#xD;
&#xD;
          -  Patients with an ileostomy or colostomy&#xD;
&#xD;
          -  Patients with documented reaction to metoclopramide.&#xD;
&#xD;
          -  Patients with a hemoglobin less than 7.5 g/dl. (Patients with Crohn's disease are&#xD;
             often chronically anemic, and a hemoglobin of 7.5 g/dl or greater would allow these&#xD;
             patients to safely participate in the study.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward V Loftus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2008</study_first_posted>
  <last_update_submitted>January 7, 2008</last_update_submitted>
  <last_update_submitted_qc>January 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Edward V. Loftus, Jr., M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>capsule endoscopy</keyword>
  <keyword>computed tomography enterography</keyword>
  <keyword>colonoscopy</keyword>
  <keyword>small bowel follow-through</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

